PPM1D mutations are most frequently observed in secondary therapy-related myelodysplastic syndromes (t-MDS) (110, 115) and in patients with bronchial (116) and ovarian carcinoma (113) after chemotherapy. This evidence concerns the gene PPM1D and myelodysplastic syndrome.